NDAINTRAMUSCULAR, INTRAVENOUSINJECTABLE
Approved
Nov 2001
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
5/8 — Partial
INVANZ (ertapenem sodium) by Merck & Co. is 12. First approved in 2001.
Drug data last refreshed Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
INVANZ (ertapenem sodium) is a broad-spectrum carbapenem antibiotic administered intravenously or intramuscularly for serious bacterial infections. It treats complicated intra-abdominal infections, urinary tract infections, pneumonia, diabetic foot infections, pelvic infections, soft tissue infections, and surgical site infections. It works by inhibiting bacterial cell wall synthesis through carbapenem mechanism of action.
$0.014BPart D
LOE ApproachingDeclining
Product is in late-stage exclusivity with modest Part D volume, signaling a consolidating team focused on defending market share against generic entry.
Mechanism of Action
12.1 Mechanism of Action Ertapenem sodium is a carbapenem antibiotic [see ]. 12.3 Pharmacokinetics Average plasma concentrations (mcg/mL) of ertapenem following a single 30-minute infusion of a 1 g intravenous (IV) dose and administration of a single 1 g intramuscular (IM) dose in healthy young…
Worked on INVANZ at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.